clinical trial · NCT07219030
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
AbbVie·phase1·recruiting·n = 32
Healthy VolunteerEmraclidinePlacebo
brief summary
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
started
Oct 8, 2025
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Nov 10, 2025
official title
A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Emraclidine Following Multiple Ascending Oral Doses in Healthy Elderly Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol